In its Q1 2026 filing, ADC Therapeutics reported sustained investment in its lead ADC product ZYNLONTA and ongoing efforts to expand its label into earlier lymphoma lines, while executing a strategic restructuring that reduced global workforce and discontinued certain preclinical programs. The company’s business model centers on commercial sales of ZYNLONTA, supplemented by licensing income, supported by proprietary ADC technology. Despite operating losses typical of biotech growth phases, ADC maintains a healthy liquidity position with over $230 million in cash and a strong current ratio. Key growth drivers include label expansions, geographic approvals, and pipeline advancement of PSMA-targeting ADCs. Risks stem from regulatory hurdles, a concentrated product portfolio, and reliance on third-party manufacturing. The evolution of royalty obligations and warrant structures illustrate ongoing financial strategic maneuvers. Upcoming milestones to watch include clinical trial readouts for new indications, regulatory decisions, and capital deployment efficiency.